EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)

LP‐001, a Novel Long‐Acting EPO‐Fc Fusion Protein: A Phase I Dose‐Escalation Study of Pharmacokinetics, Safety, and Tolerability in Healthy Chinese Subjects

Jie Yang, Jiaxiang Ding, Yuanyuan Xu, Ying Wang, Cuicui Han, Heng Liu, Huan Zhou

Clinical Pharmacology in Drug Development · 2026

DOI: 10.1002/cpdd.70020 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Jie Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Anhui Medical University, Clinical Research Hospital, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Erythropoietin, Hematinics, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The objective of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of LP‐001 injection in healthy Chinese subjects. This was a single‐center, double‐blind, randomized, dose‐escalation study. Fifty‐six healthy adults were enrolled and randomly assigned to receive LP‐001 or matched placebo. A total of 156.0 drug related adverse events occurred during treatment in 38 subjects who received LP‐001 injection. The main events were grade 1 serum iron reduction and elevated triglycerides, which were considered related to the drug's erythropoietic effect and reversible. Pharmacokinetic exposure increased with dose (0.5–50 mcg·kg −1 ), but the increase in maximum plasma concentration (C max ) and area under the plasma concentration–time curve (AUC) was greater than the dose ratio (non‐linear). Pharmacodynamics showed dose‐dependent increases in hemoglobin (Hb), red blood cell count (RBC), hematocrit (HCT), and reticulocyte count (Rtc). The pharmacodynamic indicators in the 15 and 30 mcg·kg −1 multiple‐dose groups were significantly higher than those in the placebo group, and the increase in RBC count was more pronounced in the 30 mcg·kg −1 group. LP001, a long‐acting rhEPO, was safe and well‐tolerated at all doses in this Phase I study. These findings support its continued development as a treatment for myelodysplastic syndromes (MDS).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErythropoietinHematinicsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsAdultFemaleHumansMaleMiddle AgedYoung AdultArea Under CurveChinaDose-Response Relationship, DrugDouble-Blind MethodHealthy VolunteersHemoglobinsEast Asian People

Stichwörter der Autor:innen

LP‐001MDSpharmacodynamicspharmacokineticrecombinant human erythropoietinsafety

Substanzen

ErythropoietinHematinicsHemoglobinsImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • The First Affiliated Hospital of Anhui Medical University, Clinical Research Hospital, Hefei, Anhui, China.
  • Key Laboratory of Innovative Pharmaceutical Research and Clinical Evaluation Jointly Constructed by Anhui, Bengbu, Anhui, China.
  • LongBio Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Clinical Trial Center of the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.

Zitieren

APA

Yang, J., Ding, J., Xu, Y., Wang, Y., Han, C., Liu, H., & Zhou, H. (2026). LP‐001, a Novel Long‐Acting EPO‐Fc Fusion Protein: A Phase I Dose‐Escalation Study of Pharmacokinetics, Safety, and Tolerability in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70020

Vancouver

Yang J, Ding J, Xu Y, Wang Y, Han C, Liu H, et al. LP‐001, a Novel Long‐Acting EPO‐Fc Fusion Protein: A Phase I Dose‐Escalation Study of Pharmacokinetics, Safety, and Tolerability in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70020

BibTeX
@article{Yang2026,
  author = {Yang, Jie and Ding, Jiaxiang and Xu, Yuanyuan and Wang, Ying and Han, Cuicui and Liu, Heng and Zhou, Huan},
  title = {LP‐001, a Novel Long‐Acting EPO‐Fc Fusion Protein: A Phase I Dose‐Escalation Study of Pharmacokinetics, Safety, and Tolerability in Healthy Chinese Subjects},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  doi = {10.1002/cpdd.70020}
}
Kostenlos starten →